AU2014259354B2 - Bacterial artificial chromosomes - Google Patents

Bacterial artificial chromosomes Download PDF

Info

Publication number
AU2014259354B2
AU2014259354B2 AU2014259354A AU2014259354A AU2014259354B2 AU 2014259354 B2 AU2014259354 B2 AU 2014259354B2 AU 2014259354 A AU2014259354 A AU 2014259354A AU 2014259354 A AU2014259354 A AU 2014259354A AU 2014259354 B2 AU2014259354 B2 AU 2014259354B2
Authority
AU
Australia
Prior art keywords
cdna
rna
viral
bac
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014259354A
Other languages
English (en)
Other versions
AU2014259354A1 (en
Inventor
Kai DALLMEIER
Johan Neyts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KU Leuven
Original Assignee
KU Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KU Leuven filed Critical KU Leuven
Publication of AU2014259354A1 publication Critical patent/AU2014259354A1/en
Application granted granted Critical
Publication of AU2014259354B2 publication Critical patent/AU2014259354B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/69—Increasing the copy number of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
AU2014259354A 2013-04-26 2014-04-25 Bacterial artificial chromosomes Active AU2014259354B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1307528.8A GB201307528D0 (en) 2013-04-26 2013-04-26 Bacterial artificial chromosomes
GB1307528.8 2013-04-26
PCT/EP2014/058459 WO2014174078A1 (en) 2013-04-26 2014-04-25 Bacterial artificial chromosomes

Publications (2)

Publication Number Publication Date
AU2014259354A1 AU2014259354A1 (en) 2015-11-05
AU2014259354B2 true AU2014259354B2 (en) 2020-02-27

Family

ID=48626864

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014259354A Active AU2014259354B2 (en) 2013-04-26 2014-04-25 Bacterial artificial chromosomes

Country Status (17)

Country Link
US (2) US10076564B2 (enExample)
EP (2) EP3540065A1 (enExample)
JP (1) JP6501756B2 (enExample)
KR (1) KR102170609B1 (enExample)
CN (2) CN105229153A (enExample)
AU (1) AU2014259354B2 (enExample)
BR (1) BR112015026531B1 (enExample)
DK (1) DK2989205T3 (enExample)
ES (1) ES2718187T3 (enExample)
GB (1) GB201307528D0 (enExample)
HU (1) HUE042886T2 (enExample)
PL (1) PL2989205T3 (enExample)
PT (1) PT2989205T (enExample)
SI (1) SI2989205T1 (enExample)
TR (1) TR201904215T4 (enExample)
WO (1) WO2014174078A1 (enExample)
ZA (1) ZA201507795B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201716307D0 (en) 2017-10-05 2017-11-22 Univ Leuven Kath Chimeric yellow fever zika virus strain
GB201716254D0 (en) * 2017-10-05 2017-11-22 Univ Leuven Kath Live-attenuated flaviruses with heterologous antigens
WO2019204654A1 (en) * 2018-04-18 2019-10-24 Utah State University Compositions and methods for zika virus characterization and vaccine development
GB201814563D0 (en) 2018-09-07 2018-10-24 Univ Leuven Kath Chimeric flavivirus lyssavirus vaccines
AU2020273263A1 (en) 2019-04-10 2021-12-02 Katholieke Universiteit Leuven Chimeric Zika-Japanese encephalitis virus
WO2021048003A1 (en) 2019-09-13 2021-03-18 Katholieke Universiteit Leuven Chimeric filovirus vaccines
BR112022004378A2 (pt) 2019-09-13 2022-06-07 Univ Leuven Kath Vacinas para vírus lassa
AU2020353279B2 (en) * 2019-09-25 2025-12-18 Katholieke Universiteit Leuven Large vectors and methods for high-yield production
WO2021170869A1 (en) 2020-02-27 2021-09-02 Katholieke Universiteit Leuven Coronavirus vaccines
EP4743477A1 (en) * 2023-07-11 2026-05-20 ViroVet NV Vectors Expressing an Attenuated RNA Virus of the Arteriviridae Family and Their Uses
WO2025171062A1 (en) * 2024-02-06 2025-08-14 The Regents Of The University Of California iMODULON GENE CLUSTERS AND METHODS TO IDENTIFY AND USE SAME

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874259A (en) * 1997-11-21 1999-02-23 Wisconsin Alumni Research Foundation Conditionally amplifiable BAC vector
US6696281B1 (en) * 1997-02-28 2004-02-24 Acambis, Inc. Chimeric flavivirus vaccines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665600A (en) 1991-09-18 1997-09-09 Research Corporation Technologies, Inc. Pichia pastoris linear plasmids and DNA fragments thereof
US5866404A (en) 1995-12-06 1999-02-02 Yale University Yeast-bacteria shuttle vector
EP1153136A2 (en) 1998-12-09 2001-11-14 The General Hospital Corporation Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
ES2170622B1 (es) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
US6472177B1 (en) 2001-04-23 2002-10-29 Wisconsin Alumni Research Foundation Expression vector with dual control of replication and transcription
US6864087B2 (en) * 2001-07-31 2005-03-08 Wisconsin Alumni Research Foundation Method for converting single-copy BAC vectors to conditional high-copy pBAC/oriHC vectors
US20050106733A1 (en) 2001-12-25 2005-05-19 Kenzo Takada Double-stranded cyclic dna capable of proliferating as a bacterial e coli chromosome
WO2004033633A2 (en) 2002-10-04 2004-04-22 Embiosis Pharmaceuticals Compatible host/vector systems for expression of dna
US20070036827A1 (en) 2003-10-29 2007-02-15 The University Of Queensland West nile virus vaccine
US20050214838A1 (en) 2004-03-10 2005-09-29 Waclaw Szybalski Methods for mapping and sequencing nucleic acids
WO2009053988A1 (en) 2007-10-25 2009-04-30 Ramot At Tel-Aviv University Ltd. Production of bac vectors carrying viral genomes
CN101864442A (zh) 2010-05-19 2010-10-20 江苏省农业科学院 重组火鸡疱疹病毒细菌人工染色体转移载体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696281B1 (en) * 1997-02-28 2004-02-24 Acambis, Inc. Chimeric flavivirus vaccines
US5874259A (en) * 1997-11-21 1999-02-23 Wisconsin Alumni Research Foundation Conditionally amplifiable BAC vector

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VOGEL, F.R., "Nucleic Acid Vaccines", Clinical Microbiology Reviews, 1995, 8, 3, pp 406-410 *

Also Published As

Publication number Publication date
ZA201507795B (en) 2019-07-31
BR112015026531A2 (enExample) 2017-09-05
SI2989205T1 (sl) 2019-05-31
BR112015026531B1 (pt) 2023-02-07
JP6501756B2 (ja) 2019-04-17
PL2989205T3 (pl) 2019-06-28
DK2989205T3 (en) 2019-04-23
WO2014174078A1 (en) 2014-10-30
TR201904215T4 (tr) 2019-04-22
US20160206723A1 (en) 2016-07-21
EP3540065A1 (en) 2019-09-18
GB201307528D0 (en) 2013-06-12
US20190111125A1 (en) 2019-04-18
ES2718187T3 (es) 2019-06-28
CN120249337A (zh) 2025-07-04
EP2989205B1 (en) 2019-01-02
US10076564B2 (en) 2018-09-18
AU2014259354A1 (en) 2015-11-05
KR102170609B1 (ko) 2020-10-28
EP2989205A1 (en) 2016-03-02
JP2016518132A (ja) 2016-06-23
CN105229153A (zh) 2016-01-06
KR20160003032A (ko) 2016-01-08
PT2989205T (pt) 2019-04-23
HUE042886T2 (hu) 2019-07-29

Similar Documents

Publication Publication Date Title
US10076564B2 (en) Bacterial artificial chromosomes
Nickols et al. Plasmid DNA launches live-attenuated Japanese encephalitis virus and elicits virus-neutralizing antibodies in BALB/c mice
AU2018344508B2 (en) Live-attenuated flaviruses with heterologous antigens
JP2022023198A (ja) プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン
US20060280757A1 (en) Flavivirus vaccine delivery system
AU2005279303B2 (en) Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
US20230203536A1 (en) Coronavirus rna replicons and use thereof as vaccines
US11351240B2 (en) Chimeric yellow fever ZIKA virus strain
AU2004245578B2 (en) Flavivirus replicon packaging system
OA20740A (en) Lassavirus vaccines.
AU2020346382A1 (en) Lassavirus vaccines

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)